TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Macular Pigment Optical Density at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Pigment Optical Density at 15 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual motor integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital Anxiety and Depression Scale - Anxiety Score (HADS-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital Anxiety Depression Scale- Depression Score (HADS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary patency of the vascular access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MTD of ibrutinib
Endpoint domain: Adverse events/effects
Primary endpoint: Change in General Mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of SpO2 from baseline to 48 hours post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in PANSS total score at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who discontinue study treatment due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: F index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ATT index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women diagnosed with TB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival Without BPD at 36 Weeks Post Menstrual Age
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) based on incidence of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Timing of Anaphylactic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Breastfeeding Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic annulus measurement correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Solicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Solicited and Unsolicited AEs of Grade 2 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: % BOLD Response Increase Above Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in naming performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of mean plasma intact parathyroid hormone (iPTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Increase mean serum total 25-hydroxyvitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Prostate-Specific Antigen (PSA) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom from clinically driven target lesion revascularization (TLR) and significant restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of device and procedure related deaths and major adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: endoscopic disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in clinical safety laboratory data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ECG assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in vital signs (blood pressure and heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dosage of vasopressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen Group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of endometrioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Occurrences of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and 12-lead Electrocardiogram (ECG) Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the treatment with Nimotuzumab
Endpoint domain: Adverse events/effects
Primary endpoint: patients completing definitive therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Temperature difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge about food allergy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of low risk acute syncope reclassified to intermediate/high risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of intermediate risk acute syncope reclassified to low risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of intermediate risk acute syncope reclassified to high risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: voucher redemption proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Muscle activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female Sexual Functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual Experiences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Marriage Adjustment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Participants Who Were Persistent With Index Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Seropositive for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Tested Positive for Markers of Infection With Hepatitis B Virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects With Chronic and With Clinical HBV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effect of vitamin C on SSRIs treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-associated discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle of ocular deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of dosage titrations to achieve targeted INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phantom Limb Pain (PLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart Rate During the Cold Pressor Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Systolic Blood Pressure During the Cold Pressor Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Diastolic Blood Pressure During the Cold Pressor Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Salivary Cortisol Level During the Cold Pressor Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Self-report on a Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: slope of phase III (dN2) by nitrogen single breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Actual Number of Study Visits Completed by 24 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Tenofovir Plasma Concentrations (mg/mL) Detected at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Missed Doses Over Time Based on Self-Report Calendar Data
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in phosphorylation of components of the atrogene pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with recurrent CDIs
Endpoint domain: Mortality/survival
Primary endpoint: Identification of Sentinel node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient-perceived Duration of Analgesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coverage of the Clinical Target Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose to the Organs At Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With Composite Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peritonitis Incidence Rate
Endpoint domain: Adverse events/effects
Primary endpoint: fast-food calorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Functional outcome at 90-day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With ISTH-defined Clinically-relevant Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Product Compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage change from baseline of inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Favorable clinical outcome (modified Rankin score 0-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic profiling results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depression Treatment Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Autism Rating Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With HPA Axis Suppression at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With HPA Axis Suppression at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in S-Calcium Metabolism at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in S-Calcium Metabolism at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in U-Calcium Metabolism at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in semen parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Recurrence of ischemic stroke in three months after stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recurrence of ischemic stroke in six months after stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recurrence of ischemic stroke in 12 months after stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Detection of malignant breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: abnormal brain development in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects With Complete Bidirectional Conduction Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Subjects Experiencing Cardiovascular Specific Adverse Events (CSAE) Within Seven (7) Days of the Ablation Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Count of SD during electrocorticography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily duration of metabolic crisis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional patient outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression Free Survival Rate (PFS) at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Changing the frequency of stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effectiveness in improving grades of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Effectiveness in changing duration of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: deoxycholate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Community-acquired pneumonia resulting in hospitalization and/or death
Endpoint domain: Mortality/survival
Primary endpoint: Hospital-acquired pneumonia diagnosed >2 days following hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Absence of Recurrence of Reflux Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of GH peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sputum percent neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in QTcF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 4 neutropenia for >/= 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Febrile neutropenia with Grade 4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: 30 sec chair rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain level using the Brief Pain Inventory (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain intensity using the 11-Point Numeric Rating Scale (11-NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Glycosylated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with clinically significant abnormal findings in hematology parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant abnormal findings in clinical chemistry parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Driving Impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relapse of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Hematologic Improvement (HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of acute urinary retention (AUR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of procedure code for prostate surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Full Scale Intelligence Quotient (FSIQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Elimination half life (T1/2) of the Ara H2 in sublingual placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half life (T1/2) of the Ara H2 in buccal placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half life (T1/2) of the Ara H2 in vestibular placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean cardiac reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short-term memory of verbal material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual-spatial material
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nasal congestion reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants in Complete Histologic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of lixivaptan treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of lixivaptan treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ultrasound enthesitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of TTR-CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of child's sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Levels of FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in 24-hour urine citrate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic Evidence of Successful Subacromial Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first syncope recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tacrolimus values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mediastinoscopies prevented
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Volume Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient satisfaction post-counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient anxiety pre-counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient anxiety post-counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients received red-cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite of in-hospital complications and all-cause mortality by day-30
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety Disorders Interview Schedule
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Benevolent Rounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Malevolent Rounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Surface Area and Volume of the Treated Nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate (ORR) in Patients With Metastatic HER2 Negative Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Response Rate (ORR) in Patients With Triple Negative Breast Cancer (TNBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite endpoint of all-cause mortality, cerebrovascular accident, myocardial infarction or urgent target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: BARC type-2, -3 or -5 bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients consenting for assessment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the Plasma Concentration versus Time Curve (AUC) of thiotepa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Stable Disease Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes